NAFDAC’s Reporting Drive Puts Pharmaceutical Compliance and Consumer Safety Under Scrutiny

• Stronger Pharmacovigilance, Product Traceability and Recall Procedures Are Essential to Tackling Fake and Substandard Medicines

The National Agency for Food and Drug Administration and Control (NAFDAC) has urged Nigerians to report suspected fake, substandard and unregistered medical products, as well as adverse reactions to medicines, vaccines and medical devices. The directive highlights the importance of regulatory compliance, post-market surveillance and corporate accountability in protecting public health.

The agency is encouraging consumers, healthcare professionals and businesses to use designated digital platforms and reporting channels to flag suspected violations and safety concerns. These include the MedSafety application for adverse reaction reporting and the Greenbook application for suspected falsified or unregistered medical products.

From a compliance perspective, the initiative reinforces a critical principle: regulatory responsibility does not end when a medical product receives approval or enters the market. Manufacturers, importers, distributors and other regulated stakeholders must continue to monitor product safety, respond to emerging risks and maintain systems capable of identifying and addressing potential violations.

Pharmacovigilance as a Compliance Obligation

Pharmacovigilance involves the detection, assessment and prevention of adverse effects associated with medicines and other medical products. NAFDAC’s reporting framework allows information from patients and healthcare professionals to contribute to the identification of potential safety concerns and inform regulatory action.

For pharmaceutical companies and marketing authorisation holders, effective pharmacovigilance requires more than receiving complaints. It involves maintaining appropriate procedures for collecting safety information, documenting suspected adverse reactions, escalating significant concerns and meeting applicable reporting obligations.

Organisations that fail to identify or properly manage emerging safety signals risk exposing patients to preventable harm, alongside potential regulatory, financial and reputational consequences.

Healthcare providers and consumers also have an important role. Reporting a suspected adverse reaction does not automatically establish that a product caused the reaction. Rather, the information enables the relevant authorities to investigate and assess whether further action is warranted.

Product Verification and Supply Chain Accountability

The circulation of counterfeit, falsified and substandard medicines presents a challenge for regulators and legitimate businesses alike. Products with questionable registration details, altered expiry dates, compromised packaging or uncertain distribution histories may pose risks to patients and undermine confidence in the pharmaceutical supply chain.

NAFDAC has advised consumers to verify product registration through its official platforms before purchasing or using regulated medical products.

For businesses, this places renewed emphasis on supplier due diligence, procurement controls, inventory management and traceability. Distributors and retailers should obtain products through authorised channels, retain relevant transaction records and establish procedures for isolating suspicious stock.

Compliance teams should also ensure that product registration information, batch numbers, expiry dates and supplier documentation can be verified when concerns arise. These controls can help organisations identify affected products quickly and cooperate effectively with regulatory investigations.

Recall Procedures and Corporate Responsibility

NAFDAC has also reminded regulated stakeholders that product recalls must follow established procedures. Recall notifications are expected to contain key information, including the product name and registration number, manufacturer or marketing authorisation holder, batch details, expiry date, distribution records, reasons for the recall and proposed corrective actions.

This requirement underscores the importance of having documented recall plans before a safety incident occurs. Businesses should be able to identify affected batches, trace products through distribution networks, notify relevant parties and maintain records demonstrating that corrective measures were implemented.

Delays in escalating safety concerns or initiating appropriate corrective action can increase consumer exposure and complicate regulatory intervention. Senior management should therefore ensure that quality assurance, regulatory affairs, supply chain and pharmacovigilance teams operate within a coordinated accountability framework.

From Public Reporting to Effective Enforcement

NAFDAC’s appeal demonstrates that consumer reporting is an important component of market surveillance, but reporting alone cannot eliminate unsafe products. Its effectiveness depends on the agency’s ability to assess complaints, investigate credible leads and take proportionate action where violations are established

For pharmaceutical businesses, the message is clear: compliance must extend across the entire product lifecycle, from sourcing and registration to distribution, safety monitoring and recall management.

Ultimately, protecting Nigerians from unsafe medical products requires shared responsibility among regulators, manufacturers, distributors, healthcare professionals and consumers. Strong internal controls, timely reporting and transparent cooperation with authorities will be essential to improving medicine safety and strengthening confidence in Nigeria’s healthcare system.